Abstract
This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.
Original language | English (US) |
---|---|
Journal | Clinical Lymphoma, Myeloma and Leukemia |
DOIs | |
State | Accepted/In press - Jan 1 2020 |
Keywords
- Hodgkin lymphoma
- Multiple myeloma
- Non-Hodgkin lymphoma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research